Ezetimibe and PCSK9 inhibitors have shown positive outcomes related to MACE in patients with clinical ASCVD; however, several clinical outcomes trials are still in progress for BDA and for the investigational drug, inclisiran. The gene discussed is PCSK9; the disease is atherosclerosis.